KR900015730A - 정신장해 치료방해 - Google Patents

정신장해 치료방해 Download PDF

Info

Publication number
KR900015730A
KR900015730A KR1019900004984A KR900004984A KR900015730A KR 900015730 A KR900015730 A KR 900015730A KR 1019900004984 A KR1019900004984 A KR 1019900004984A KR 900004984 A KR900004984 A KR 900004984A KR 900015730 A KR900015730 A KR 900015730A
Authority
KR
South Korea
Prior art keywords
fluorophenyl
indole
chloro
ethyl
acid addition
Prior art date
Application number
KR1019900004984A
Other languages
English (en)
Other versions
KR920008703B1 (ko
Inventor
페레가르트 옌스
스카르스펠트 토오르벤
Original Assignee
할도르 크리스텐센, 포올 엘가르트 페데프센
하. 룬트베크 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10654774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900015730(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 할도르 크리스텐센, 포올 엘가르트 페데프센, 하. 룬트베크 아크티에 셀스카브 filed Critical 할도르 크리스텐센, 포올 엘가르트 페데프센
Publication of KR900015730A publication Critical patent/KR900015730A/ko
Application granted granted Critical
Publication of KR920008703B1 publication Critical patent/KR920008703B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

내용 없음.

Description

정신장해 치료방해
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 이형성신경이완제 5-클로로-1-(4-플루오로페닐)-3-(1-(2-(2-이미다졸리디논-1-일) 에틸)-4-피페리딜)-1H-인돌,
    또는 제약학적으로 허용되는 그의 산부가염을 그를 필요로 하는 환자에게 효과적인 양 투여하는 단계로 이루어지는 실질적으로 어떤 추체외로의 부작용도 일으키지 않고서 사람의 정신질환을 치료하는 방법.
  2. 5-클로로-1-(4-플루오로페닐)-3-(1-(2-(2-이미다졸리디논-1-일) 에틸)-4-피페리딜)-1H-인돌 또는 제약학적으로 허용되는 그의 산 부가염을 그를 필요로 하는 환자에게 효과적인 양 투여하는 단계로 이루어지는, 선택적으로 뇌의 복면 피개지역에서의 도파민 뉴우런을 차단함으로써, 실질적으로 혹질 치밀부에서의 도파민 뉴우런을 차단하지 않고서, 실질적으로 어떤 추체외로의 부작용도 일으키지 않고서 사람의 정신질환을 치료하는 방법.
  3. 제1항 또는 제2항에 있어서, 5-클로로-1-(4-플루오로페닐)-3-(1-(2-(2-이미다졸리디논-1-일) 에틸)-4-피페리딜)-1H-인돌 또는 제약학적으로 허용되는 그의 산 부가염을 단위 투여량 형태로 투여하는 것을 특징으로 하는 방법.
  4. 제3항에 있어서, 단위투여량에는 0.001 내지 7.0mg의 5-클로로-1-(4-플루오로페닐)-3-(1-(2-(2-이미다졸리디논-1-일) 에틸)-4-피페리딜)-1H-인돌 또는 제약학적으로 허용되는 그의 산 부가염이 포함되는 것을 특징으로 하는 방법.
  5. 5-클로로-1-(4-플루오로페닐)-3-(1-(2-(2-이미다졸리디논-1-일) 에틸)-4-피페리딜)-1H-인돌 또는 제약학적으로 허용되는 산 부가염을 그를 필요로 하는 환자에게 효과적인 양 투여하는 단계로 이루어지는, 사람의 정신분열증의 음성 증상을 치료하는 방법.
  6. 5-클로로-1-(4-플루오로페닐)-3-(1-(2-(2-이미다졸리디논-1-일) 에틸)-4-피페리딜)-1H-인돌 또는 제약학적으로 허용되는 그의 산 부가염을 효과적인 양 투여하는 단계로 이루어지는, 정신분열증 환자에 있어서 수면의 질을 개선시키는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900004984A 1989-04-11 1990-04-11 사람의 정신질환 치료용 제약학적 조성물 KR920008703B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB89-8085.7 1989-04-11
GB8908085.7 1989-04-11
GB898908085A GB8908085D0 (en) 1989-04-11 1989-04-11 New therapeutic use

Publications (2)

Publication Number Publication Date
KR900015730A true KR900015730A (ko) 1990-11-10
KR920008703B1 KR920008703B1 (ko) 1992-10-08

Family

ID=10654774

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900004984A KR920008703B1 (ko) 1989-04-11 1990-04-11 사람의 정신질환 치료용 제약학적 조성물

Country Status (18)

Country Link
US (1) US5112838A (ko)
EP (1) EP0392959B1 (ko)
JP (1) JP2775191B2 (ko)
KR (1) KR920008703B1 (ko)
AT (1) ATE157005T1 (ko)
AU (1) AU621735B2 (ko)
CA (1) CA2014208C (ko)
CY (1) CY2082B1 (ko)
DE (2) DE69031290T2 (ko)
DK (1) DK0392959T3 (ko)
GB (1) GB8908085D0 (ko)
HK (1) HK1002825A1 (ko)
IE (1) IE81157B1 (ko)
IL (1) IL94021A (ko)
NL (1) NL980008I1 (ko)
NZ (2) NZ233179A (ko)
SG (1) SG48234A1 (ko)
ZA (1) ZA902785B (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK206591D0 (da) * 1991-12-23 1991-12-23 Lundbeck & Co As H Behandling af psykoser
DK8492D0 (da) * 1992-01-23 1992-01-23 Lundbeck & Co As H Behandling af psykoser
DK123493D0 (da) * 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
JP2000507544A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
AU745641B2 (en) * 1997-10-27 2002-03-28 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
GB9805716D0 (en) * 1998-03-17 1998-05-13 Merck Sharp & Dohme Therapeutic agents
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
PT1458888E (pt) * 2001-12-10 2011-06-01 Novartis Ag Métodos para tratar a psicose e a esquizofrenia baseados em polimorfismos no gene do cntf
US20050101788A1 (en) * 2002-03-27 2005-05-12 Jacopo Zanon Method for manufacture of sertindole
RU2005135454A (ru) * 2003-05-16 2006-06-27 Пфайзер Продактс Инк. (Us) Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
MY142329A (en) * 2004-08-24 2010-11-15 Janssen Pharmaceutica Nv Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070212412A1 (en) * 2005-09-08 2007-09-13 H. Lundbeck A/S Stable solid formulation of sertindole
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
TW200821296A (en) * 2006-06-01 2008-05-16 Lundbeck & Co As H Use of sertindole for the preventive treatment of suicidal behaviour
US20100021891A1 (en) * 2006-06-12 2010-01-28 Bernard Lerer Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
EP2567696A1 (en) 2006-11-22 2013-03-13 Seaside Therapeutics, Inc. Compositions for treating autism spectrum disorder
WO2008106144A2 (en) * 2007-02-28 2008-09-04 Nupathe Inc. Implants for the treatment of psychiatric states
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359468A (en) * 1981-02-25 1982-11-16 Boehringer Ingelheim Ltd. Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy

Also Published As

Publication number Publication date
US5112838A (en) 1992-05-12
EP0392959A3 (en) 1992-05-06
DK0392959T3 (da) 1999-03-29
ATE157005T1 (de) 1997-09-15
SG48234A1 (en) 1998-04-17
CY2082B1 (en) 1998-10-16
ZA902785B (en) 1991-06-26
JPH02290872A (ja) 1990-11-30
NZ243765A (en) 1997-09-22
GB8908085D0 (en) 1989-05-24
IE81157B1 (en) 2000-05-03
EP0392959A2 (en) 1990-10-17
DE69031290T2 (de) 1998-01-02
NZ233179A (en) 1996-12-20
HK1002825A1 (en) 1998-09-18
AU621735B2 (en) 1992-03-19
JP2775191B2 (ja) 1998-07-16
IL94021A (en) 1994-01-25
NL980008I1 (nl) 1998-05-06
AU5303790A (en) 1990-10-18
EP0392959B1 (en) 1997-08-20
CA2014208C (en) 1996-03-19
DE69031290D1 (de) 1997-09-25
CA2014208A1 (en) 1990-10-11
IL94021A0 (ko) 1991-01-31
DE19875011I2 (de) 2004-07-01
KR920008703B1 (ko) 1992-10-08
IE901051L (en) 1990-10-11

Similar Documents

Publication Publication Date Title
KR900015730A (ko) 정신장해 치료방해
ATE339956T1 (de) Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
KR950703951A (ko) 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac)
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
RU2002124141A (ru) Применение миртазапина для лечения расстройств сна
KR970005283A (ko) 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도
ATE214926T1 (de) Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit
ATE247462T1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
KR880004810A (ko) 소화성 궤양 치료제
EA200600757A1 (ru) Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
EA199800781A1 (ru) Применение 2-(3,4-диметоксициннамоил) аминобензойной кислоты для изготовления лекарственного средства для лечения или предотвращения рестеноза
KR880013556A (ko) 도파민수용체 효능제의 용도
KR890001555A (ko) 요산 배설용 조성물
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염
KR930007452A (ko) 벤조디아제핀-금단 환자의 불안증 치료방법
KR910018026A (ko) α-페닐-α피리딜알칸산 유도체를 함유하는 배뇨장애증상 치료제
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
KR880011077A (ko) 유효치료 물질로서 사용하기 위한 tert- 부틸아미노-3(페닐-2'-펜옥시)-1-프로판올-2 및 그의 산부가염

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090925

Year of fee payment: 18

EXPY Expiration of term